Why Krystal Biotech, Inc. (KRYS) stock moved
Krystal Biotech, Inc. (KRYS) shares fell 1.1% to $335.42 as of July 21, 2026, a modest decline from the prior close of $339.22. BestStocks flagged the session as a major change for KRYS. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for KRYS, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
KRYS fell 1.1% to $335.42
KRYS fell 1.1% in its latest session, moving from $339.22 to $335.42.
What it means for Krystal Biotech, Inc. investors
For Krystal Biotech, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Krystal Biotech, Inc. (KRYS) moved +3.82% from $341.79 to $354.86 on 2026-07-17; Krystal Biotech, Inc. (KRYS) moved +3.18% from $339.43 to $350.24 on 2026-07-15. Weighing against that: Negative session, down 1.1%; Krystal Biotech, Inc. (KRYS) moved -6.61% from $363.44 to $339.43 on 2026-07-14. Wall Street's consensus price target sits at $357.00, implying +6.4% upside from $335.42. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 13 days out, the next report is the most likely near-term test of the move.
KRYS price reaction
KRYS last traded at $335.42, down $3.80 (-1.12%) from the previous close of $339.22. The session traded on 0.4× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $335.42 and $378.15, and it currently sits about 0% of the way up that band.
Bullish and bearish analyst opinions on Krystal Biotech, Inc. (KRYS)
The consensus analyst price target on Krystal Biotech, Inc. (KRYS) is $357.00, 6.4% above the recent $335.42. Over the past 90 days analysts logged 0 upgrades, 9 maintains, and 0 downgrades. Here is how the bullish and bearish cases on KRYS line up.
The bullish case
- Wall Street's consensus price target of $357.00 implies +6.4% upside from $335.42.
- The Street's most bullish target is $474.00 (+41.3%).
- Krystal Biotech, Inc. (KRYS) moved +3.82% from $341.79 to $354.86 on 2026-07-17.
The bearish case
- The most bearish analyst target is $300.00 (-10.6%).
- Negative session, down 1.1%.
- Krystal Biotech, Inc. (KRYS) moved -6.61% from $363.44 to $339.43 on 2026-07-14.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for KRYS
Frequently asked questions about KRYS
Why did Krystal Biotech, Inc. (KRYS) stock move?
KRYS fell 1.1% to $335.42. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did KRYS stock fall?
KRYS lost 1.12% ($3.80) versus the prior close of $339.22, last trading at $335.42 on 0.4× average volume.
When is Krystal Biotech, Inc.'s next earnings date?
KRYS's next earnings report is estimated for 2026-08-03 — about 13 days away.
What is the analyst price target for KRYS?
The consensus analyst price target for KRYS is $357.00, about 6.4% above the current $335.42. Over the past 90 days, analysts recorded 0 upgrades, 9 maintains, and 0 downgrades.
How BestStocks tracks KRYS
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared KRYS-specific materiality thresholds, triggering an evidence check. It draws on 6 tracked change events for KRYS, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.